Latest News

• IRONMAN: An International Registry To Improve Outcomes in Men wit...

  Press Releases by UroToday April 18, 2018

  

  PCCTC investigator Dr. Lorelei Mucci discusses innovative new registry initiative. ...

  Learn More

• PCCTC-Developed Apalutamide Gains FDA Approval

  Press Releases by admin March 9, 2018

  

  On February 14, 2018, the Food and Drug Administration (FDA) approved the next-generation AR antagonist apalutamide (Erleada™, Janssen Biotech, Inc.) for pati...

  Learn More

• PCCTC Muscadine (MPX) Study Finds Activity in Select Genotypes

  Press Releases by admin December 19, 2017

  

  A pre-planned subset analysis using a polymorphism of the superoxide dismutase-2 (SOD2) gene as a biomarker shows promising results in the 25% of men with the A...

  Learn More

• The PCCTC Salutes Its Very Own Angie Avery

  Press Releases by admin November 7, 2017

  

  Celebrating Veterans Week 2017, we salute Angie Avery, PCCTC Project Coordinator. ...

  Learn More

• Timeline of PCCTC Clinical Contributions

  Press Releases by admin November 6, 2017

  

  The Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) presents the evolution of the PCCTC, abiraterone, and enzalutamide. ...

  Learn More

• Early Development Led by the PCCTC, FDA Approval Now Sought for A...

  Press Releases by Jason Harris - OncLive October 12, 2017

  

  A new drug application (NDA) has been submitted to the FDA for apalutamide (ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (C...

  Learn More